Abstract
Medications that target the noradrenergic system are important therapeutics for depression and anxiety disorders. More recently, clinical studies have shown that the α2-noradrenergic receptor (α2AR) agonist guanfacine can decrease stress-induced smoking relapse during acute abstinence, suggesting that targeting the noradrenergic system may aid in smoking cessation through effects on stress pathways in the brain. Acetylcholine (ACh), like the nicotine in tobacco, acts at nicotinic acetylcholine receptors (nAChRs) to regulate behaviors related to anxiety and depression. We therefore investigated interactions between guanfacine and ACh signaling in tests of anxiolytic and antidepressant efficacy in female and male C57BL/6J mice, focusing on the amygdala as a potential site of noradrenergic/cholinergic interaction. The antidepressant-like effects of guanfacine were blocked by shRNA-mediated knockdown of α2AR in amygdala. Knockdown of the high-affinity β2 nAChR subunit in amygdala also prevented antidepressant-like effects of guanfacine, suggesting that these behavioral effects require ACh signaling through β2-containing nAChRs in this brain area. Ablation of NE terminals prevented the anxiolytic- and antidepressant-like effects of the nicotinic partial agonist cytisine, whereas administration of the cholinesterase antagonist physostigmine induced a depression-like phenotype that was not altered by knocking down α2AR in the amygdala. These studies suggest that ACh and NE have opposing actions on behaviors related to anxiety and depression and that cholinergic signaling through β2-containing nAChRs and noradrenergic signaling through α2a receptors in neurons of the amygdala are critical for regulation of these behaviors.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Glavin GB. Stress and brain noradrenaline: a review. Neurosci Biobehav Rev. 1985;9:233–43.
Isingrini E, Perret L, Rainer Q, Amilhon B, Guma E, Tanti A, et al. Resilience to chronic stress is mediated by noradrenergic regulation of dopamine neurons. Nat Neurosci. 2016;19:560–3.
Morilak DA, Barrera G, Echevarria DJ, Garcia AS, Hernandez A, Ma S, et al. Role of brain norepinephrine in the behavioral response to stress. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:1214–24.
Caudill MM, Hunter AM, Cook IA, Leuchter AF. The antidepressant treatment response index as a predictor of reboxetine treatment outcome in major depressive disorder. Clin EEG Neurosci. 2015;46:277–84.
Strawn JR, Compton SN, Robertson B, Albano AM, Hamdani M, Rynn MA. Extended release guanfacine in pediatric anxiety disorders: a pilot, randomized, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2017;27:29–37.
Fox H, Sinha R. The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals. Adv Pharmacol. 2014a;69:217–65.
Fox H, Sofuoglu M, Sinha R. Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals. J Psychopharmacol (Oxf, Engl). 2015;29:312–23.
Gold PW. The organization of the stress system and its dysregulation in depressive illness. Mol Psychiatry. 2015;20:32–47.
Sofuoglu M, Rosenheck R, Petrakis I. Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress. Addict Behav. 2014;39:428–33.
McKee SA, Potenza MN, Kober H, Sofuoglu M, Arnsten AF, Picciotto MR, et al. A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation. J Psychopharmacol (Oxf, Engl). 2015;29:300–11.
Fox HC, Morgan PT, Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacology. 2014b;39:1527–37.
Mineur YS, Bentham MP, Zhou WL, Plantenga ME, McKee SA, Picciotto MR. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology. 2015;232:3539–49.
Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, et al. Human tobacco smokers in early abstinence have higher levels ofbeta2* nicotinic acetylcholine receptors than nonsmokers. J Neurosci. 2006;26:8707–14.
Hannestad JO, Cosgrove KP, DellaGioia NF, Perkins E, Bois F, Bhagwagar Z, et al. Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I]5IA single photon emission computed tomography. Biol Psychiatry. 2013;74:768–76.
Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, et al. Persistentbeta2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry. 2012;169:851–9.
Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, et al. Imaging changes in synaptic acetylcholine availability in living human subjects. J Nucl Med. 2013;54:78–82.
Janowsky DS, Overstreet DH. Cholinergic dysfunction in depression. Pharmacol Toxicol. 1990;3:100–11.
Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL. Mood and behavioral effects of physostigmine on humans are accompanied by elevations in plasma beta-endorphin and cortisol. Science. 1980;209:1545–6.
Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, et al. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior. Proc Natl Acad Sci USA. 2013;110:3573–8.
Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci. 2010;31:580–6.
Lin LC, Lewis DA, Sibille E. A human-mouse conserved sex bias in amygdala gene expression related to circadian clock and energy metabolism. Mol Brain. 2011;4:18.
Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature. 2011;471:358–62.
Clark CP, Brown GG, Archibald SL, Fennema-Notestine C, Braun DR, Thomas LS, et al. Does amygdalar perfusion correlate with antidepressant response to partial sleep deprivation in major depression? Psychiatry Res. 2006;146:43–51.
Jiang L, Kundu S, Lederman JD, Lopez-Hernandez GY, Ballinger EC, Wang S, et al. Cholinergic signaling controls conditioned fear behaviors and enhances plasticity of cortical-amygdala circuits. Neuron. 2016;90:1057–70.
Mineur YS, Fote GM, Blakeman S, Cahuzac EL, Newbold SA, Picciotto MR. Multiple nicotinic acetylcholine receptor subtypes in the mouse amygdala regulate affective behaviors and response to social stress. Neuropsychopharmacology. 2016;41:1579–87.
Tully K, Bolshakov VY. Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Mol Brain. 2010;3:15.
Ferry B, Roozendaal B, McGaugh JL. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol Psychiatry. 1999;46:1140–52.
Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol. 2002;12:527–44.
Carrier GO, Bishop VS. The interaction of acetycholine and norepinephrine on heart rate. J Pharmacol Exp Ther. 1972;180:31–37.
Devore S, Linster C. Noradrenergic and cholinergic modulation of olfactory bulb sensory processing. Front Behav Neurosci. 2012;6:52.
Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS, Picciotto MR, et al. Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. Nicotine Tob Res. 2015;17:486–95.
Jonsson G, Hallman H, Ponzio F, Ross S. DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine)--a useful denervation tool for central and peripheral noradrenaline neurons. Eur J Pharmacol. 1981;72:173–88.
Ross SB, Renyl AL. On the long-lasting inhibitory effect of N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP 4) on the active uptake of noradrenaline. J Pharm Pharmacol. 1976;28:458–9.
Grzanna R, Berger U, Fritschy JM, Geffard M. Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J Histochem Cytochem. 1989;37:1435–42.
Scullion GA, Kendall DA, Sunter D, Marsden CA, Pardon MC. Central noradrenergic depletion by DSP-4 prevents stress-induced memory impairments in the object recognition task. Neuroscience. 2009;164:415–23.
Srinivasan J, Schmidt WJ. Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats. J Neural Transm (Vienna). 2004;111:13–26.
Mineur YS, Abizaid A, Rao Y, Salas R, DiLeone RJ, Gundisch D, et al. Nicotine decreases food intake through activation of POMC neurons. Science. 2011;332:1330–2.
Hommel JD1, Sears RM, Georgescu D, Simmons DL, DiLeone RJ. Local gene knockdown in the brain using viral-mediated RNA interference. Nature Medicine 2003;9(12):1539–44.
Benavides DR, Quinn JJ, Zhong P, Hawasli AH, DiLeone RJ, Kansy JW, et al. Cdk5 modulates cocaine reward, motivation, and striatal neuron excitability. J Neurosci 2007;27(47): 12967–12976
Zolotukhin S, Byrne BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, et al Recombinant adenoassociated virus purification using novel methods improves infectious titer and yield. Gene therapy 1999;6(6): 973–985.
Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;2:632–5.
Mineur YS, Mose TN, Blakeman S, Picciotto MR (2017). Hippocampal alpha7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice. Br J Pharmacol. https://www.ncbi.nlm.nih.gov/pubmed/28264149
West CH, Ritchie JC, Boss-Williams KA, Weiss JM. Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol. 2009;12:627–41.
Morilak DA, Fornal CA, Jacobs BL. Effects of physiological manipulations on locus coeruleus neuronal activity in freely moving cats. I. Thermoregulatory challenge. Brain Res. 1987;422:17–23.
Aston-Jones G1, Kalivas PW. Brain norepinephrine rediscovered in addiction research. Biol Psychiatry. 2008;63(11):1005-6.
Vizi ES, Ronai A, Harsing LG, Knoll J (1978). Presynaptic modulation by norepinephrine and dopamine of acetylcholine release in the peripheral and central nervous system. In: Jenden DJ, editor. Cholinergic mechanisms and psychopharmacology. Springer US: Boston, MA, pp 587–603.
Picciotto MR, Higley MJ, Mineur YS. Acetylcholine as a neuromodulator: cholinergic signaling shapes nervous system function and behavior. Neuron. 2012;76:116–29.
Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999;402:181–4.
Berridge CW, Waterhouse BD. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev. 2003;42:33–84.
Simoes AP, Machado NJ, Goncalves N, Kaster MP, Simoes AT, Nunes A, et al. Adenosine A2A receptors in the amygdala control synaptic plasticity and contextual fear memory. Neuropsychopharmacology. 2016;41:2862–71.
Buffalari DM, Grace AA. Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of alpha-2 and beta receptor activation. J Neurosci. 2007a;27:12358–66.
Ramos BP, Arnsten AF. Adrenergic pharmacology and cognition: focus on the prefrontal cortex. Pharmacol Ther. 2007;113:523–36.
Mineur YS, Somenzi O, Picciotto MR. Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice. Neuropharmacology. 2007;52:1256–62.
Papke RL, Heinemann SF. Partial agonist properties of cytisine on neuronal nicotinic receptors containing the beta 2 subunit. Mol Pharmacol. 1994;45:142–9.
Buffalari DM, Grace AA. Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of alpha-2 and beta receptor activation. J Neurosci. 2007b;27:12358–66.
Mineur YS, Eibl C, Young G, Kochevar C, Papke RL, Gundisch D, et al. Cytisine-based nicotinic partial agonists as novel antidepressant compounds. J Pharmacol Exp Ther. 2009;329:377–86.
Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6:254–85.
Acknowledgements
Funding
This work was supported by NIH grants DA033945 (ORWH, NIDA, FDA) and MH077681.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Mineur, Y.S., Cahuzac, E.L., Mose, T.N. et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. Neuropsychopharmacol 43, 2118–2125 (2018). https://doi.org/10.1038/s41386-018-0024-x
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41386-018-0024-x
This article is cited by
-
Medial prefrontal cortex acetylcholine signaling mediates the ability to learn an active avoidance response following learned helplessness training
Neuropsychopharmacology (2025)
-
Phase synchrony between prefrontal noradrenergic and cholinergic signals indexes inhibitory control
Nature Communications (2025)
-
Consistent decline of acetylcholine in microbiota-gut-brain axis mediates antibiotic-induced anxiety via regulating hippocampus microglial activation
Molecular Psychiatry (2025)
-
Promising Antidepressant Potential: The Role of Lactobacillus rhamnosus GG in Mental Health and Stress Response
Probiotics and Antimicrobial Proteins (2025)
-
The role of the adrenalectomy in the management of pheochromocytoma: the experience of a Portuguese referral center
Endocrine (2024)
